To explore the contribution of TRIM33 to cardiac fibrosis and cardiac function in vivo, we injected the TRIM33 overexpression adeno-associated virus 9 (AAV9-TRIM33)-treated mice and the sham-treated mice with Ang II (15 mg/kg/day subcutaneously for 28 days) [15]. This evidence concerns the gene TRIM33 and fibrosis.